The paradox of digital cardio-geriatrics: why did optimal treatment adherence and mobile technologies fail to reduce hospitalizations in the AFFIRMO trial?

Osypchuk A.V.

Main
Publications
The paradox of digital cardio-geriatrics: why did optimal treatment adherence and mobile technologies fail to reduce hospitalizations in the AFFIRMO trial?

November 3, 2026

Osypchuk A.V.

УДК: УДК 616.12-008.313.2-053.9:004.38

DOI: DOI:10.32471/umj.1680-3051.282187

Keywords :

AFFIRMO trial,

atrial fibrillation,

comprehensive geriatric assessment (CGA),

hospitalization,

integrated ABC pathway (iABC),

mobile health (mHealth),

multimorbidity

Resume

The international cluster-randomized AFFIRMO trial demonstrated a neutral effect of an integrated digital care approach combining the integrated ABC pathway (iABC) and comprehensive geriatric assessment (CGA) on reducing unplanned hospitalizations among older patients with atrial fibrillation and multimorbidity. The absence of a significant clinical benefit may be attributable to the already high baseline uptake of oral anticoagulation across participating centers (97.3%) and the limited long-term engagement of older adults with the mobile application.

References

1. Lip G.Y.H., Proietti M., Ainsworth J. et al. (2026) Integrated care management and comprehensive geriatric assessment using a mHealth-based approach in older multimorbid patients with atrial fibrillation: the AFFIRMO cluster-randomised trial. Lancet Reg. Health Eur., 70: 101832. DOI: 10.1016/j.lanepe.2026.101832.
2. Lip G.Y.H. (2026) AFFIRMO — atrial fibrillation integrated approach in frail, multimorbid and polymedicated older people. ESC Congress 2026, Munich, Germany.
3. Hindricks G., Potpara T., Dagres N. et al. (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J., 42(5): 373–498. DOI: 10.1093/eurheartj/ehaa612.
4. Joglar J.A., Chung M.K., Armbruster A.L. et al. (2024) 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol., 83(1): 109–279. DOI: 10.1016/j.jacc.2023.08.017.
5. Van Gelder I.C., Rienstra M., Bunting K.V. et al. (2024) 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J., 45(36): 3314–3414. DOI: 10.1093/eurheartj/ehae176.
6. Potpara T., Romiti G.F., Sohns C. et al. (2024) The 2024 European Society of Cardiology Guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician’s perspective. Thromb. Haemost., 124(12): 1087–1094. DOI: 10.1055/a-2434-9244.
7. Lip G.Y.H., Chen Y., Li M. et al. (2026) Integrated management of atrial fibrillation with digital health support: a pooled analysis of individual participant data from the mAFA-II and MIRACLE-AF trials. Cardiovasc. Res., 122(14): 1936–1946. DOI: 10.1093/cvr/cvag173.
8. Kirchhof P. (2026) Discussant review — AFFIRMO. ESC Congress 2026, Munich, Germany.